Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Jan 19.

Published in final edited form as: Circulation. 2009 Dec 28;121(2):276–292. doi: 10.1161/CIRCULATIONAHA.109.895771

Telomere-telomerase and p53 function. A, Telomere shortening in DOXO-treated CPCs: nuclei (blue) were stained with a telomere probe (magenta). Lymphoma cells with long (L5178Y-R, 48 kbp) and short (L5178Y-S, 7 kbp) telomeres are shown for comparison. The average telomere length is indicated together with the degree of telomeric shortening and the fraction of cells with telomeres equal/shorter than 8 kbp. B, Telomerase activity was comparable in control and DOXO-treated CPCs. Samples treated with RNase were used as negative and HeLa cells as positive control. C and D, DOXO activates the DNA-damage response in CPCs. Immunoblotting for Bax and Bad are shown in the upper part of panel D. Protein expression is shown as fold changes with respect to c. See Figure 1 for symbols.

Telomere-telomerase and p53 function. A, Telomere shortening in DOXO-treated CPCs: nuclei (blue) were stained with a telomere probe (magenta). Lymphoma cells with long (L5178Y-R, 48 kbp) and short (L5178Y-S, 7 kbp) telomeres are shown for comparison. The average telomere length is indicated together with the degree of telomeric shortening and the fraction of cells with telomeres equal/shorter than 8 kbp. B, Telomerase activity was comparable in control and DOXO-treated CPCs. Samples treated with RNase were used as negative and HeLa cells as positive control. C and D, DOXO activates the DNA-damage response in CPCs. Immunoblotting for Bax and Bad are shown in the upper part of panel D. Protein expression is shown as fold changes with respect to c. See Figure 1 for symbols.